Client news

A&O Shearman advises Bridgepoint on financing for the acquisition of Obagi Medical

A&O Shearman advises Bridgepoint on financing for the acquisition of Obagi Medical
Published Date
Jun 4 2026
Related people
Image of Gordon Mak
Gordon MakPartner, New York
Image of Nick Hallam
Nick HallamPartner, London
Image of Ramone Bedi
Ramone BediSenior Associate, London
Photo of Sykes Mitchell
Sykes MitchellInternational Associate, New York
Image of Edward Crosby
Edward CrosbyAssociate, London
Image of Angela Zhang
Angela ZhangLaw Clerk, New York
A&O Shearman has represented Bridgepoint, one of the world’s leading mid-market investors, on the financing of its agreement to acquire Obagi Medical, the dermatological skincare and aesthetics business of Waldencast plc.

Obagi Medical operates in the medical aesthetics and prescription skincare market, offering a range of products designed to address a variety of skin conditions including hyperpigmentation, acne, and the visible signs of aging. 

"We are happy to have supported Bridgepoint on the financing of this significant acquisition. This transaction highlights A&O Shearman's deep expertise in complex healthcare and life sciences financings, backed by our global platform across Europe, the US and beyond.”

The A&O Shearman team that advised Bridgepoint was led by Debt Finance partners Gordon Mak and Nick Hallam, with support from associate Sykes Mitchell and law clerk Angela Zhang.

The team also included senior associate Ramone Bedi and associate Edward Crosby.

Related capabilities